Regulatory and quality compliance
The company manufactures APIs and finished products for clinical and commercial use under licenses and approvals.
- Scope
- Production and release of regulated pharmaceutical products
- Materiality
- high
Magle Chemoswed Holding
Magle Chemoswed Holding AB is a Swedish life-science group based in Malmö with operations centered on pharmaceutical chemistry and drug-delivery technologies. Through its subsidiaries, it develops and manufactures APIs, biopolymer-based healthcare products, and diagnostic-related products, while also providing contract development, manufacturing, and laboratory services.
| % | |
|---|---|
| Pharmaceutical CMO/CDMO | 45% Development and manufacturing of APIs and finished pharmaceutical products for clients. |
| Biopolymers and dextran solutions | 25% CDMO and manufacturing services focused on dextran and biopolymer-based healthcare products. |
| Proprietary DSM and dextran products | 20% Direct sales and distribution of degradable starch microsphere and dextran products. |
| Contract laboratory and consulting services | 10% Analytical development, material characterization, and solid-state analysis services. |
Customers include pharmaceutical companies that need development, scale-up, and manufacturing support for APIs and...
- Pharmaceutical developers and manufacturersprimary
Buy API development, formulation, manufacturing, packaging, and logistics support for drug programs.
- Clinical-trial sponsors and clinicssecondary
Buy trial-ready pharmaceutical products and related manufacturing services for study use.
- Medical device and diagnostics customersprimary
Buy DSM, dextran, and biopolymer-based products for medical applications.
- Pharma and biotech R&D clientssecondary
Buy contract laboratory, material characterization, and process-development services.
The group is headquartered in Malmö, Sweden, with core operations also in Berlin, Germany and Køge, Denmark...
- •Headquartered in Malmö, Sweden
- •Core operations in Berlin and Køge
- •Revenue reported across Sweden, Europe ex Sweden, and other territories
- •International sales matter for DSM and product distribution
- •Multi-site footprint supports regulated manufacturing and delivery
The group’s strategy is built around integrated pharmaceutical development and manufacturing, combining internal R&D...
01
Advance proprietary DSM and dextran productsmedium-term
Own products can create differentiated demand and licensing value beyond pure contract manufacturing.
02
Maintain integrated CDMO executionshort-term
End-to-end development and manufacturing capabilities support customer retention and switching costs.
03
Expand distribution and outlicensing pathwaysmedium-term
Partners can broaden market reach while reducing the capital burden of commercialization.
The business depends on successful development, regulatory compliance, and customer adoption of specialized...
Development and commercialization risk
DSM, dextran, and other proprietary programs depend on successful technical and clinical progress.
- Scope
- Internal product pipeline and licensing value
- Materiality
- high
Integration and acquisition risk
The group has a portfolio of acquired businesses and assets that must be integrated operationally and financially.
- Scope
- Goodwill, intangibles, and operating model
- Materiality
- high
Customer and project concentration
CDMO revenue can depend on a limited number of projects, programs, or distributors at any time.
- Scope
- Third-party development and product sales
- Materiality
- medium
Geographic and currency exposure
Operations and sales span Sweden, Germany, Denmark, and other territories.
- Scope
- Cross-border revenue and costs
- Materiality
- medium
Revenue recognition by stream
Affects quarterly revenue mix and margin comparability
Goodwill and intangible asset impairment
Can materially affect earnings and equity
Purchase price allocation and depreciation
Influences depreciation, amortization, and book value
Consolidation eliminations
Affects reported group revenue and expenses
: 11/08/2026